Source comparison
Tesamorelin for HIV Lipodystrophy: Treatment Comparison
Patients with HIV-associated lipodystrophy have limited FDA-approved pharmacological options. The table below compares tesamorelin for HIV lipodystrophy to alternative interventions based on mechanism, efficacy, administration, and metabolic considerations. Te
This comparison does not assign a generated winner or score.
- Patients with HIV-associated lipodystrophy have limited FDA-approved pharmacological options. The table below compares tesamorelin for HIV lipodystrophy to alternative interventions based on mechanism, efficacy, administration, and metabolic considerations.
- Tesamorelin 2mg daily
- GHRH analogue. Stimulates endogenous GH release, increases IGF-1, enhances visceral lipolysis
- 15–20% at 26 weeks (pivotal trials)
- Daily subcutaneous injection
- Increases fasting glucose 4–6 mg/dL; monitor for impaired glucose tolerance
- VAT reaccumulates to baseline within 26 weeks
- FDA-approved, VAT-specific, requires ongoing use. Most evidence-based option for visceral fat reduction in HIV lipodystrophy
- Exogenous Growth Hormone (off-label)
- Direct GH receptor agonism. Increases lipolysis but continuous receptor occupancy
- 10–15% (small trials, not HIV-specific)
- Daily or alternate-day subcutaneous injection
- Higher insulin resistance risk than tesamorelin; more frequent hyperglycemia
- Reaccumulation similar to tesamorelin
- Not FDA-approved for this indication; higher adverse event profile including edema, arthralgias, carpal tunnel syndrome
- Metformin (off-label)
- AMPK activation, improved insulin sensitivity, modest reduction in hepatic glucose output
- 5–8% VAT reduction in observational studies
- Oral, once or twice daily
- Improves glucose tolerance in insulin-resistant patients
- Benefit maintained if continued
- Does not address GH pathway; minimal VAT effect compared to tesamorelin; used adjunctively in diabetic patients
- Lifestyle modification (diet, exercise)
- Caloric deficit, resistance training for lean mass preservation
- 3–5% VAT reduction (intensive programs)
- Ongoing behavioral adherence
- Improves glucose control if sustained
- Reaccumulation if adherence lapses
- Does not reverse GH deficiency; insufficient as monotherapy for significant VAT reduction in HIV lipodystrophy
- Surgical lipectomy
- Physical removal of dorsocervical or abdominal subcutaneous fat deposits
- Not applicable to VAT (intra-abdominal fat not accessible surgically)
- One-time procedure
- No metabolic impact
- Permanent for removed depots; does not prevent VAT accumulation
- Addresses cosmetic lipoatrophy and buffalo hump; does not reduce visceral fat or cardiovascular risk
- The bottom line: tesamorelin for HIV lipodystrophy is the only FDA-approved pharmacological intervention with clinical trial evidence demonstrating visceral adipose tissue reduction in this population. Alternative approaches address different components of the syndrome or provide marginal VAT benefit. Combination strategies. Tesamorelin for VAT reduction plus dermal fillers for facial lipoatrophy. Are common in comprehensive management.